Plasmaide Advanced Endurance + Recovery Orange (Epigenhealth Pty Ltd)
Product Name
Plasmaide Advanced Endurance + Recovery Orange
Sponsor
ARTG
386475
Date of review outcome
Date of publication
Mar-2025
Outcome
Medicine is no longer permitted to be supplied
Is it safe to continue using this medicine?
Yes, based on the sponsor's certification. However, use of this medicine may pose a safety risk for some people. Follow the recommended actions below.
What action should consumers take?
Seek advice from a doctor if you have been taking this medicine to treat asthma, attention deficit hyperactivity disorder (ADHD), cardiovascular disease, diabetes, for controlling blood pressure, or reducing inflammation in patients with traumatic brain injury.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to claims related to: blood health, brain function, gut health, or eye health; improving sports performance, recovery, energy, or reducing muscle soreness and fatigue; being anti-inflammatory, or having antimicrobial benefits; accelerating healing, lowering cholesterol, delivering nutrients, or boosting immunity; and sleep.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to claims related to: blood health, brain function, gut health, or eye health; improving sports performance, recovery, energy, or reducing muscle soreness and fatigue; being anti-inflammatory, or having antimicrobial benefits; accelerating healing, lowering cholesterol, delivering nutrients, or boosting immunity; and sleep.
Review scope
Targeted
Information reviewed
ARTG Record, Labels, Website
Issues related to safety
The website for this medicine contained claims specified in ‘What action should consumers take?’ above. Some of these claims are not permitted for listed medicines without prior evaluation or approval from the TGA. References to non-permitted claims have the potential to lead consumers to delay access to timely advice or treatment from a suitably qualified health professional when required, which may result in adverse outcomes.
While advertising of this nature is unacceptable, these claims have been removed from the website and current data indicates this medicine is unlikely to pose an immediate risk to consumer health and safety.
While advertising of this nature is unacceptable, these claims have been removed from the website and current data indicates this medicine is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
The website for this medicine contained claims specified in 'What action should consumers take?’ above. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
Actions taken during the review
The TGA required the sponsor to correct the issues with this medicine. The sponsor cancelled this medicine and withdrew it from further supply.